Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia.

Chemotherapy failure remains a challenge when treating patients with acute myeloid leukemia (AML), who often suffer from persistent or relapsed disease. The multidrug resistance (MDR) mediated by efflux transporters of the ATP binding cassette (ABC) superfamily is a major obstacle for successful chemotherapy. The present study aimed to elucidate whether the expression of ABC transporters was associated with prognostic factors and responses to chemotherapy in patients with AML, with particular focus on whether co-expression of multiple ABC transporters resulted in a worse prognosis. In the present study, the mRNA expression levels of ABC transporters and in bone marrow (BM) mononuclear cell (MNC) samples from 96 patients with AML and in the peripheral blood (PB) MNC samples from 22 normal individuals were investigated using reverse transcription-quantitative polymerase chain reaction analysis. It was revealed that and were expressed at higher levels in patients with AML compared with normal individuals, whereas had a lower expression level. The expression of in patients with AML was significantly lower than in normal individuals (P<0.001). Patients risk status was associated with (P=0.037), (P=0.047), (P=0.015) and (P=0.027). The 4 genes were expressed a significantly higher levels in the poor response group compared with the good response group (, P=0.014; , P=0.021; , P=0.005; , P=0.009). The overexpression of the 4 ABC transporters and the complete remission rate were inversely correlated (P<0.001). These results suggest that the co-expression of multiple ABC transporters may contribute to a worse prognosis in AML.